NIFTY, or Non-Invasive Fetal Trisomy, is a simple blood test that can identify disorders associated with an irregular number of chromosomes in the fetus including also chromosomal deletions and duplications, Unlike an amniocentesis prenatal examination, the NIFTY test poses no risk to the fetus or the mother.
The NIFTY test is available in two versions: NIFTY-Basic and NIFTY-Extended. NIFTY-Basic tests for the three most common syndromes and the sex chromosomes. NIFTY-Extended tests all 23 pairs of the fetal chromosomes and can also identify deletions and duplications. This extended test has successfully identified more than 40 syndromes thus far.
Extensive clinical trial have been conducted regarding the most common syndromes –Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18) and Patau syndrome (Trisomy 13), and NIFTY has demonstrated a 100% sensitivity rate. Therefore NIFTY is defined as a screening test with an accuracy rate of over 99% for these syndromes. The accuracy rate of the NIFTY test regarding the less common disorders is still being studied and has yet to be determined.
NIFTY is conducted from the 10th week of pregnancy and onwards and is appropriate also for pregnancies with twins.
NIFTY is unable to check for or identify every potential fetal defect and it is therefore advisable to consult with your physician concerning the most appropriate and relevant tests for you.
For the pregnant woman, NIFTY is just like any other blood test. The blood sample is drawn at one of the clinics that conducts the test and is sent to the BGI laboratories. Utilizing advanced technology, the labs analyze the free DNA found in the mother's blood, some 10% of which originates from the fetus. AML Israel handles the local logistical aspect of the testing.